Skip to main content

Table 1 Baseline clinical and renal pathological features of LN patients with or without deep remission

From: Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV

Baseline characteristics

Deep remission

p

Achieved (n = 55)

Not achieved (n = 14)

Sex (percentage female)

48 (87.3)

9 (64.2)

0.01

Age (years)

39.1 ± 12.4

39.9 ± 10.7

0.3

BMI (kg/m2)

22.4 ± 3.3

20.9 ± 2.3

0.5

Systolic blood pressure (mmHg)

127.8 ± 17.0

136.4 ± 21.5

0.2

Diastolic blood pressure

79.7 ± 13.6

83.6 ± 14.5

0.3

Disease duration (years)

5.1 ± 6.8

8.0 ± 6.4

0.4

SLEDAI

15.6 ± 4.8

13.0 ± 4.8

0.4

SDI

0.4 ± 0.6

0.6 ± 0.8

0.7

Proteinuria (g/gCr)

2.7 ± 2.1

3.7 ± 1.8

0.07

eGFR (mL/min)

76.6 ± 28.2

72.2 ± 32.8

0.9

Anti-dsDNA antibody (IU/mL)

177 ± 274

112 ± 116

0.6

Anti-cardiolipin antibody (IU/mL)

21.8 ± 30.7

14.7 ± 28.5

0.5

Lupus anticoagulant-positive (%)

3 (5.5)

1 (7.1)

0.6

CH50 (U/ml)

17.1 ± 9.3

24.4 ± 14.2

0.06

Prednisolone (mg/day)

45.5 ± 15.1

37.1 ± 10.1

0.08

Induction therapy

 IVCY (%)

29 (52.7)

5 (35.7)

0.4

 MMF (%)

8 (14.5)

2 (14.3)

0.9

 Tacrolimus (%)

8 (14.5)

2 (14.3)

0.9

 PSL monotherapy (%)

6 (10.9)

2 (14.3)

0.8

 Others (%)

4 (7.3)

3 (21.4)

0.1

Renal pathological findings

 ISN/RPS classification

  III or III + V (%)

26 (47.3)

5 (35.7)

0.4

  IV or IV + V (%)

29 (52.7)

9 (64.3)

0.4

Endocapillary hypercellularity (%)

39.2 ± 18.6

46.0 ± 30.2

0.5

Leukocyte infiltration (%)

2.0 ± 4.9

2.2 ± 4.1

0.4

Subendothelial hyaline deposits (%)

29.1 ± 30.2

30.1 ± 28.9

0.3

Fibrinoid necrosis/karyorrhexis (%)

7.0 ± 11.1

8.1 ± 18.1

0.3

Cellular crescents (%)

7.0 ± 11.1

8.1 ± 18.1

0.7

Interstitial inflammation (%)

2.1 ± 3.7

2.3 ± 7.4

0.5

Glomerular sclerosis (%)

2.5 ± 7.1

3.9 ± 8.2

0.4

Fibrous crescents (%)

2.1 ± 2.0

2.2 ± 3.1

0.7

Tubular atrophy (%)

2.8 ± 4.7

3.3 ± 5.9

0.5

Interstitial fibrosis (%)

4.7 ± 6.8

5.1 ± 5.9

0.6

Activity index

5.2 ± 3.0

5.1 ± 3.8

0.5

Chronicity index

1.4 ± 0.4

1.4 ± 1.3

0.7

  1. dsDNA double-stranded DNA, IVCY intravenous cyclophosphamide, MMF mycophenolate mofetil, SDI Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, SLEDAI Systemic Lupus Erythematosus Disease Activity Index